6 research outputs found
Current ESPGHAN guidelines for celiac disease in pediatric age, tertiary care center experience: a proposal for further simplification
According to the 2012 ESPGHAN criteria for
diagnosis of celiac disease (CD), duodenal biopsy (DB)
can be avoided in children with a clear malabsorption
syndrome, anti-tissue transglutaminase IgA (tTG2) ≥ 10x
the cut-off, anti-endomysium IgA (EMA) and HLA
DQ2/DQ8 genes. The aim of this study is to report our
experience and evaluate the accuracy of the actual
guidelines.
Patients and methods: This is a retrospective study
conducted on all patients diagnosed CD from 2012 to
2018 in our Center. For all patients enrolled were
analyzed: data of family history, symptoms, serology,
genetics, Marsh grade and follow-up.
Results: A total of 481 children [mean age 6,4 yrs; F:M=
1.8:1] were included in the study. The mean age of
patients who were not subject to DB was lower (4.51 yrs)
comparing with patients that received DB (6.48 yrs). Out
of the 256 patients with anti-tTG2 ≥ 10 fold, 121
underwent DB because of mild symptoms (84/121) or no
symptoms (37/121). In all cases Marsh type 3 was found
and HLA haplotypes was compatible with CD diagnosis.
Conclusions: Our study confirms that the serology has a
primary importance to diagnose CD, regardless of the
symptoms. These data suggest that biopsy and HLA
haplotypes search, in presence of anti-tTG2 IgA ≥ 10x
the cut-off, are wasteful and unhelpful for the patients
A four-time-recurring typical complete Kawasaki syndrome successfully treated with intravenous immunoglobulin: a case report with literature review
Misuse of serological screening tests for celiac disease in children: A prospective study in Italy
New orphan disease therapies from the proteome of industrial plasma processing waste- a treatment for aceruloplasminemia
Abstract Plasma-derived therapeutic proteins are produced through an industrial fractionation process where proteins are purified from individual intermediates, some of which remain unused and are discarded. Relatively few plasma-derived proteins are exploited clinically, with most of available plasma being directed towards the manufacture of immunoglobulin and albumin. Although the plasma proteome provides opportunities to develop novel protein replacement therapies, particularly for rare diseases, the high cost of plasma together with small patient populations impact negatively on the development of plasma-derived orphan drugs. Enabling therapeutics development from unused plasma fractionation intermediates would therefore constitute a substantial innovation. To this objective, we characterized the proteome of unused plasma fractionation intermediates and prioritized proteins for their potential as new candidate therapies for human disease. We selected ceruloplasmin, a plasma ferroxidase, as a potential therapy for aceruloplasminemia, an adult-onset ultra-rare neurological disease caused by iron accumulation as a result of ceruloplasmin mutations. Intraperitoneally administered ceruloplasmin, purified from an unused plasma fractionation intermediate, was able to prevent neurological, hepatic and hematological phenotypes in ceruloplasmin-deficient mice. These data demonstrate the feasibility of transforming industrial waste plasma fraction into a raw material for manufacturing of new candidate proteins for replacement therapies, optimizing plasma use and reducing waste generation
Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience
AIM: To check the safety and efficacy of boceprevir/ telaprevir with peginterferon/ribavirin for hepatitis C virus (HCV) genotype 1 in the real-world settings. METHODS: This study was a non-randomized, observational, prospective, multicenter. This study involved 47 centers in Italy. A database was prepared for the homogenous collection of the data, was used by all of the centers for data collection, and was updated continuously. All of the patients enrolled in this study were older than 18 years of age and were diagnosed with chronic infection due to HCV genotype 1. The HCV RNA testing was performed using COBAS-TaqMan2.0 (Roche, LLQ 25 IU/mL). RESULTS: All consecutively treated patients were included. Forty-seven centers enrolled 834 patients as follows: Male 64%; median age 57 (range 18-78), of whom 18.3% were over 65; mean body mass index 25.6 (range 16-39); genotype 1b (79.4%); diagnosis of cirrhosis (38.2%); and fibrosis F3/4 (71.2%). The following drugs were used: Telaprevir (66.2%) and PEG-IFN-alpha2a (67.6%). Patients were naĂŻve (24.4%), relapsers (30.5%), partial responders (14.8%) and null responders (30.3%). Overall, adverse events (AEs) occurred in 617 patients (73.9%) during the treatment. Anemia was the most frequent AE (52.9% of cases), especially in cirrhotic. The therapy was stopped for 14.6% of the patients because of adverse events or virological failure (15%). Sustained virological response was achieved in 62.7% of the cases, but was 43.8% in cirrhotic patients over 65 years of age. CONCLUSION: In everyday practice, triple therapy is safe but has moderate efficacy, especially for patients over 65 years of age, with advanced fibrosis, nonresponders to peginterferon + ribavirin